Cell Therapy Biotech Talaris Ends Two Kidney Transplant Trials, Restructures While Talaris Therapeutics is ending two clinical tests of its cell therapy in kidney transplant patients, a third study in the autoimmune condition scleroderma is continuing. Meanwhile, the biotech’s restructuring plan is pursuing “strategic alternatives” that could include a merger or sale. Information Courtesy By:…